Refine
Year of publication
Language
- English (21) (remove)
Has Fulltext
- yes (21)
Is part of the Bibliography
- no (21)
Keywords
- PBPK (3)
- biorelevant dissolution (2)
- modeling and simulation (2)
- Data sharing (1)
- IVIV_E (1)
- PBBM (1)
- PBPK modelling (1)
- amorphous solid dispersions (1)
- aprepitant (1)
- bio-enabling formulations (1)
- biopharmaceutics (1)
- bio‐enabling formulations (1)
- clinically relevant dissolution specifications (1)
- dissolution modeling (1)
- drug–drug interaction (DDI) (1)
- etravirine (1)
- food effect (1)
- global change (1)
- habitat destruction (1)
- in vitro in vivo extrapolation (IVIVE) (1)
- in-vitro–in-vivo correlation (1)
- ketoconazole (1)
- land use (1)
- mechanistic oral absorption modeling (1)
- nano-sized drugs (1)
- oral drug products (1)
- pharmacogenetics (1)
- pharmacokinetics (1)
- pharmacokinetics/pharmacodynamics (PK/PD) (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- precipitation (1)
- product performance (1)
- zolpidem (1)
Institute
A webinar series that was organised by the Academy of Pharmaceutical Sciences Biopharmaceutics focus group in 2021 focused on the challenges of developing clinically relevant dissolution specifications (CRDSs) for oral drug products. Industrial scientists, together with regulatory and academic scientists, came together through a series of six webinars, to discuss progress in the field, emerging trends, and areas for continued collaboration and harmonisation. Each webinar also hosted a Q&A session where participants could discuss the shared topic and information. Although it was clear from the presentations and Q&A sessions that we continue to make progress in the field of CRDSs and the utility/success of PBBM, there is also a need to continue the momentum and dialogue between the industry and regulators. Five key areas were identified which require further discussion and harmonisation.